Fundraising FoxEvlaBio
3 known investors
Find your way into EvlaBio
Sign up to find every way you can get introduced to EvlaBio
- Your email: who you already know at EvlaBio, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the EvlaBio team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
EVL Bio is developing a selective anti-FGFR4 monoclonal antibody therapy to treat left ventricular hypertrophy (LVH) in patients with chronic kidney disease (CKD). The therapy blocks pathological FGF23–FGFR4 signaling in cardiomyocytes to prevent maladaptive cardiac hypertrophy and fibrosis.
Founders & leadership
Investors · 3
AdBio partnerslisted by AdBio partnersParis
How we know: AdBio partners's portfolio page · Not right? Tell us
Kurma Partnerslisted by Kurma PartnersParis · $162K – $10.8M
How we know: Kurma Partners's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us
Frequently asked questions
- What does EvlaBio do?
- EVL Bio is developing a selective anti-FGFR4 monoclonal antibody therapy to treat left ventricular hypertrophy (LVH) in patients with chronic kidney disease (CKD). The therapy blocks pathological FGF23–FGFR4 signaling in cardiomyocytes to prevent maladaptive cardiac hypertrophy and fibrosis.
- Who founded EvlaBio?
- EvlaBio was founded by Robert Kirmeier, Wenzel von der Heydte.
- Who are EvlaBio's investors?
- EvlaBio's investors include AdBio partners, Khanu, Kurma Partners.